Document is current
Any future updates will be listed below
-
Authors
Woodfin, Ashley A.
Yam, Clinton
Teshome, Mediget
Kuerer, Henry M.
Hunt, Kelly K.
Meric-Bernstam, Funda
Schaverien, Mark
Barcenas, Carlos H.
Sun, Susie X. https://orcid.org/0000-0002-2179-7739
- License Information
-
More Information
Article History
Received: 31 July 2023
Accepted: 19 October 2023
First Online: 16 November 2023
Disclosures
: Kelly Hunt is a member of the Medical Advisory Board of ArmadaHealth and AstraZeneca, and has received research funding to her institution from Cairn Surgical, Eli Lilly & Co., and Lumicell. Funda Meric-Bernstam has received consulting fees from AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd, Calibr (a division of Scripps Research), DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd, GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, LegoChem Bio, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, and Zymeworks; is a member of the Advisory Committee of Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, Theratechnologies, and Zentalis; has received sponsored research (paid to the institution) from Aileron Therapeutics, Inc., AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd, Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co.; and has received honoraria and other (travel-related) funding from the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), and the Cholangiocarcinoma Foundation. Ashley A. Woodfin, Clinton Yam, Mediget Teshome, Henry M. Kuerer, Mark Schaverien, Carlos H. Barcenas, and Susie X. Sun have no conflicts of interest to declare.
